Active Ingredient(s): Insulin Glargine-aglr
FDA Approved: * December 17, 2021
Pharm Company: * ELI LILLY CO
Category: Diabetes

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Rezvoglar Overview

Insulin glargine [GLAR geen], sold under the brand name Lantus among others, is a long-acting insulin, used in the management of type I and type II diabetes.[6] It is typically the recommended long acting insulin in the United Kingdom.[7][contradictory] It is used once a day as an injection just under the skin.[6] Effects generally begin an hour after use.[6] Common side effects include low blood sugar, problems a...

Read more Rezvoglar Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Rezvoglar Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Insulin Glargine-aglr
  • Injection: 100 Units/ml, 100unit/ml, 10ml(100units/ml), 300 Units/ml, 3ml(100units/ml)
  • Solution: 300 Units/3ml (100 Units/ml), 300 Units/ml (300 Units/ml), 300units/ml (300units/ml), 450 Units/1.5ml (300 Units/ml), 900 Units/3ml (300 Units/ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Insulin Glargine-aglr or a similar ingredient: (4 results)